Multivalent Vaccines Is Increasingly Being Demanded Globally

Multivalent Vaccines


A multivalent or polyvalent vaccine is designed to immunize against two or more strains of the same microorganism, or against two or more microorganisms. The term “multivalent/polyvalent vaccine” is commonly used to depict either an immunization with the capacity to shield against more than one illness or a vaccine that protects against multiple strains of a solitary pathogen.

Drivers & Restraints

The growth of this market is majorly attributed to the high prevalence of infectious diseases, increasing company initiatives to enhance vaccine Research & Development, growing government support for vaccine development, and the rising focus on immunization. However, the huge capital investments required for developing vaccines may restrain market growth.

Sample Link Here:



Conjugate Vaccines

Inactivated and Subunit Vaccines

Live Attenuated Vaccines

Toxoid Vaccines

Recombinant Vaccines




Regional Analysis

The market has been segment into North America, South America, Europe, Asia-Pacific, and Middle East and Africa. North America accounted for the largest share of the vaccines market in 2018.

Purchase Link Here:


  • GlaxoSmithKline, plc
  • Pfizer, Inc.
  • Merck & Co., Inc.
  • Sanofi Pasteur SA
  • Astellas Pharma Inc.
  • CSL Limited
  • Emergent BioSolutions, Inc.
  • Johnson & Johnson
  • Serum Institute of India Pvt. Ltd.
  • Mitsubishi Tanabe Pharma Corporation
  • Daiichi Sankyo
  • Panacea Biotec